COST-UTILITY ANALYSIS OF OMALIZUMAB COMPARED WITH STANDARD THERAPY IN PATIENTS OVER TWELVE YEARS OLD WITH SEVERE ASTHMA FROM THE COLOMBIAN HEALTH SYSTEM PERSPECTIVE

被引：0

作者：

Ariza, J. G. ^{[1
]}

Acosta, T. ^{[2
]}

Pinzon, J. F. ^{[1
]}

机构：

[1] Novartis Corp, Bogota, Colombia

[2] Univ La Sabana, Bogota, Colombia

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 04期

关键词：

D O I：

10.1016/j.jval.2012.03.311

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A56 / A56

页数：1

共 39 条

[1] COST UTILITY ANALYSIS OF OMALIZUMAB THERAPY FOR SEVERE ASTHMA PATIENTS IN THAILAND
Sakul-isariyaporn, C.
Lertiendumrong, J.
Vasavid, C.
Pachanee, K.
VALUE IN HEALTH, 2011, 14 (07) : A495 - A495
[2] COST-UTILITY ANALYSIS OF MEPOLIZUMAB VERSUS BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA IN THE COLOMBIAN HEALTHCARE SYSTEM
Rodriguez, E.
Garcia Nuncira, C. Y.
VALUE IN HEALTH, 2020, 23 : S350 - S350
[3] Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia
Antonio Buendia, Jefferson
Patino, Diana Guerrero
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 575 - 580
[4] ESTIMATING THE BUDGET IMPACT OF ADDING OMALIZUMAB TO STANDARD THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA FROM PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
Suzuki, C.
Santoni, N. B.
Silva, N. L.
VALUE IN HEALTH, 2013, 16 (03) : A232 - A233
[5] Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia
Jefferson Antonio, Buendia
Patino, Diana Guerrero
Lopez Moreno, Melisa
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 299 - 305
[6] Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom
Karnon, J.
Tolley, K.
Oyee, J.
Jewitt, K.
Ossa, D.
Akehurst, R.
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (06) : 1609 - 1621
[7] COST-UTILITY OF BICTEGRAVIR/TENOFOVIR ALAFENAMIDE/EMTRICITABINE IN NAIVE PATIENTS OVER 18 YEARS OF AGE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION, FROM THE COLOMBIAN'S HEALTH SYSTEM PERSPECTIVE
Vasquez, E.
Lasalvia, P.
Rosselli, D.
Lenis, W.
Barbosa, D.
Diaz-Ortega, M. H.
VALUE IN HEALTH, 2023, 26 (06) : S125 - S125
[8] COST ANALYSIS OF OMALIZUMAB USE IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA WITHIN THE MEXICAN PUBLIC HEALTH CARE SYSTEM
Lemus-Carmona, E.
Reyes-Lopez, A.
Jimenez Aranda, P.
VALUE IN HEALTH, 2012, 15 (07) : A563 - A564
[9] A cost-utility analysis of single maintenance and reliever (SMART) therapy as compared to step 3 fixed-dose therapy in patients aged 12 years or more with uncontrolled asthma
Rodriguez-Martinez, Carlos E.
Sossa-Briceno, Monica P.
Castro-Rodriguez, Jose A.
PEDIATRIC PULMONOLOGY, 2025, 60 (01)
[10] ECONOMIC EVALUATION OF OMALIZUMAB ADD-ON THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA FROM THE PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
Suzuki, C.
Santoni, N. B.
Silva, N. L.
VALUE IN HEALTH, 2013, 16 (03) : A234 - A234

← 1 2 3 4 →